Loading page…

Chandra Bhagat Pharma Ltd (CBPL) · mywealthgrid

About

Chandra Bhagat Pharma Ltd operates in Pharmaceuticals within the Healthcare sector.

Face value: ₹10

Market cap

₹37 Cr

P/E

40.7×

P/B

1.1×

Dividend yield

ROE

9.7%

ROCE

17.9%

Debt / equity

0.08

OPM

3.3%

EPS (TTM)

₹1.2

Book value

₹43.9

52-week high

₹83.7

52-week low

₹30.0

₹49.4-40.6%1Y

Beta

0.32

Damps index moves

Volatility (1y)

78.5%

Annualised, daily returns

RSI (14)

57.5

Neither overbought nor oversold

Rel. strength (1y)

-45.9%

Behind the market

Beta is measured against NIFTY 50 over three years of weekly returns — 1 moves with the index, above 1 amplifies it, below 1 damps it.

Quick read

rule-based

Pros

+Profit CAGR of 74.2% over the last 5 years
+Almost debt-free (debt/equity 0.1)
+High promoter holding of 73% with no pledge

Cons

−Low return on equity of 6% (3-yr avg)
−Thin operating margin of 3.3%

Research score

Structured signal from quality, growth, valuation and momentum.

45/100

Business quality: 35
Growth: 50
Valuation

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry Compare top 5 side-by-side

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Standalone figures · ₹ crore

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	71	94	120	221	89	116
COGS	60	81	107	180	65	97
Gross profit	11	13	13	41	24	19
	8	10	10	48	23	15
Operating profit (EBITDA)	3	3	3	-7	1	4
OPM %	4.7%	2.9%	2.8%	-3.2%	0.7%	3.3%
Depreciation	0	0	0	1	1	1
Interest	3	3	2	1	2	2
	0	2	0	11	3	3
Profit before tax	0	1	1	2	1	4
Tax	0	0	0	1	0	1
Tax %	32.1%	27.3%	22.4%	32.3%	26.5%	25.8%
	0	1	1	2	1	3
PAT margin %	0.3%	0.9%	0.8%	0.7%	1%	2.6%
EPS (₹)	0.3	1.1	1.2	—	—	—
EPS adjusted (₹)	—	1.1	1.2	2	1.1	4
Annual report	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	Annual report for Mar 2026

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	—	8	8	8	8	8
Reserves	—	19	20	21	22	26
	—	5	4	1	2	3
	72	40	29	71	69	59
Total equity & liabilities	72	72	61	102	102	94
	—	0	1	3	3	3
CWIP	—	—	—	—	—	—
Investments	0	0	0	0	0	2
	71	72	60	99	99	90
Total assets	72	72	61	102	102	94

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	8	12	5	6	-6	9
	0	0	-0	-2	-1	-0
	-5	-10	-4	-6	2	-6
Net cash flow	2	3	1	-1	-4	2
Free cash flow	8	12	5	4	-7	8
CFO / Operating profit %	231.6%	464.9%	158%	—	-892.2%	240%

Compounded sales growth

7 years: —
5 years: 11%
3 years: -1%
1 year: 31%

Compounded profit growth

7 years: —
5 years: 74%
3 years: 50%
1 year: 255%

Stock price CAGR

10 years: —
5 years: —
3 years: 12%
1 year: -37%

Return on equity

7 years

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Standalone figures

Ratio	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	15.5%	13.5%	10.9%	18.7%	26.5%	16.6%
EBITDA margin %	4.7%	2.9%

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2024	Mar 2025	Sep 2025	Mar 2026
	69.29%	71.2%	72.19%	73.02%
	0.48%	0.61%	0.61%	0%
DII	0%	0%	0%	0%
Government	0%	0%	0%	0%
	30.23%	28.19%	27.2%	26.98%
No. of shareholders	315	316	301	280

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

No fund holdings on record

No scheme among the 32 fund houses on record reported a position in Chandra Bhagat Pharma Ltd. Portfolios are published monthly by each AMC; coverage is still partial.

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Annual reports

Documents link to external sources (exchange filings, company investor pages).

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

No events on record

Corporate actions, results dates and filings will appear here once ingested.

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

5 announcementsExport CSV

1 Oct 2026, 9:45 amInsider Trading / SAST

Closure of Trading Window

Closure of Trading Window PDF

Loading announcements…

Date	Category	Subject	Filing
1 Oct 2026, 9:45 am	Insider Trading / SAST Closure of Trading Window	Closure of Trading Window	PDF
30 Sept 2026, 9:36 pm	Company Update Change in Management	Announcement under Regulation 30 (LODR)-Change in Management	PDF
3 Sept 2026, 6:02 pm	AGM/EGM AGM	Shareholder Meeting / Postal Ballot-Scrutinizer''s Report	PDF
1 Sept 2026, 6:11 pm	AGM/EGM AGM	Shareholder Meeting / Postal Ballot-Outcome of AGM	PDF
20 Aug 2026, 3:18 pm	Company Update General	Corrigendum Of AGM Notice	PDF

Leverage
Current ratio	2.13	1.86	2.19	1.38	1.37	1.5

Working capital
Receivable days	—	58	25	65	148	171

Return ratios
Return on assets %	0.3%	1.1%	1.5%	1.5%	0.8%	3.2%

Chandra Bhagat Pharma Ltd

Chandra Bhagat Pharma Ltd

About

Risk & technicals

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Stock price CAGR

Return on equity

Ratios

Ratio timeline

Shareholding

Quarterly record

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Annual reports

Events

No events on record

Announcements

No fund holdings on record

Not in the F&O segment

No events on record

Announcements

Annual reports

Ratio timeline

Quarterly record

Board and management

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Stock price CAGR

Return on equity